Safe and Efficacious Use of Low‐Dose Rituximab in Postpubertal Paediatric Patients With Immune Thrombocytopenia

Safe and Efficacious Use of Low‐Dose Rituximab in Postpubertal Paediatric Patients With Immune Thrombocytopenia

ABSTRACT Background Rituximab, a CD20 monoclonal antibody, is used in chronic/refractory immune thrombocytopenia (ITP). Standard dosing is 375 mg/m2 weekly for 4 weeks alongside dexamethasone. A lower dose of Rituximab at 100 mg weekly demonstrates comparable efficacy that is well tolerated. This st...

Full description

Saved in:
Bibliographic Details
Main Authors: Jennifer Darlow, Gerard Gurumurthy, Nathan Jeffreys, Lianna Reynolds, Vismay Deshani, John Grainger
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Online Access:https://doi.org/10.1002/jha2.70010
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items